Pharming Roic vs Roe Analysis

PHAR Stock

USD 9.32 0.05 0.54%

Pharming Group financial indicator trend analysis is much more than just breaking down Pharming Group NV prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pharming Group NV is a good investment. Please check the relationship between Pharming Group Roic and its Roe accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pharming Group NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Roic vs Roe

Roic vs Roe Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pharming Group NV Roic account and Roe. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Pharming Group's Roic and Roe is 0.86. Overlapping area represents the amount of variation of Roic that can explain the historical movement of Roe in the same time period over historical financial statements of Pharming Group NV, assuming nothing else is changed. The correlation between historical values of Pharming Group's Roic and Roe is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Roic of Pharming Group NV are associated (or correlated) with its Roe. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Roe has no effect on the direction of Roic i.e., Pharming Group's Roic and Roe go up and down completely randomly.

Correlation Coefficient

0.86

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Roic

Return on Invested Capital, a profitability ratio that measures the return that an investment generates for those who have provided capital, such as debt holders and equity holders.

Roe

Most indicators from Pharming Group's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pharming Group NV current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pharming Group NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

At this time, Pharming Group's Selling General Administrative is relatively stable compared to the past year. As of 12/13/2024, Issuance Of Capital Stock is likely to grow to about 4 M, while Tax Provision is likely to drop (1.5 M).

	2021	2022	2023	2024 (projected)
Total Operating Expenses	156.7M	169.8M	225.5M	236.8M
Cost Of Revenue	20.2M	17.6M	25.2M	15.2M

Total Operating Expenses Cost Of Revenue

Pharming Group fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock
Total Assets		0.98	0.92	0.64	0.97	0.9	0.19	0.38	0.23	0.7	0.76	0.96	-0.18	0.98	0.91	0.66	0.58	0.95	0.86	0.62	0.88	0.97	0.99	0.09	0.81	-0.37
Short Long Term Debt Total	0.98		0.92	0.59	0.92	0.87	0.09	0.39	0.19	0.71	0.77	0.94	-0.21	0.96	0.85	0.61	0.54	0.98	0.85	0.56	0.86	0.98	0.97	0.05	0.83	-0.38
Other Current Liab	0.92	0.92		0.68	0.83	0.72	0.19	0.39	-0.01	0.8	0.69	0.9	-0.22	0.9	0.85	0.62	0.54	0.91	0.78	0.56	0.83	0.96	0.91	0.15	0.78	-0.42
Total Current Liabilities	0.64	0.59	0.68		0.52	0.35	0.51	0.17	-0.26	0.67	0.49	0.8	0.06	0.5	0.78	0.25	0.15	0.48	0.41	0.17	0.8	0.72	0.53	0.77	0.86	-0.44
Total Stockholder Equity	0.97	0.92	0.83	0.52		0.93	0.19	0.32	0.42	0.59	0.73	0.89	-0.15	0.98	0.86	0.67	0.6	0.88	0.85	0.66	0.81	0.88	0.98	-0.04	0.71	-0.28
Property Plant And Equipment Net	0.9	0.87	0.72	0.35	0.93		0.0	0.33	0.37	0.43	0.68	0.8	-0.23	0.92	0.74	0.63	0.57	0.87	0.83	0.6	0.72	0.81	0.92	-0.18	0.6	-0.25
Current Deferred Revenue	0.19	0.09	0.19	0.51	0.19	0.0		-0.31	-0.14	0.28	0.31	0.32	0.05	0.13	0.26	-0.16	-0.2	0.0	-0.16	-0.06	0.41	0.18	0.11	0.39	0.41	-0.12
Net Debt	0.38	0.39	0.39	0.17	0.32	0.33	-0.31		0.07	0.42	-0.29	0.3	0.1	0.32	0.57	0.87	0.89	0.39	0.67	0.76	0.09	0.41	0.41	0.05	0.12	-0.12
Retained Earnings	0.23	0.19	-0.01	-0.26	0.42	0.37	-0.14	0.07		-0.11	0.15	0.09	0.37	0.31	0.13	0.26	0.3	0.15	0.29	0.45	-0.02	0.03	0.3	-0.43	-0.02	0.45
Accounts Payable	0.7	0.71	0.8	0.67	0.59	0.43	0.28	0.42	-0.11		0.44	0.7	0.04	0.66	0.69	0.52	0.47	0.7	0.57	0.54	0.7	0.77	0.67	0.2	0.72	-0.27
Cash	0.76	0.77	0.69	0.49	0.73	0.68	0.31	-0.29	0.15	0.44		0.77	-0.3	0.78	0.49	0.04	-0.06	0.75	0.42	0.06	0.83	0.73	0.72	0.01	0.78	-0.32
Non Current Assets Total	0.96	0.94	0.9	0.8	0.89	0.8	0.32	0.3	0.09	0.7	0.77		-0.1	0.89	0.92	0.51	0.42	0.87	0.74	0.48	0.92	0.97	0.9	0.33	0.92	-0.38
Non Currrent Assets Other	-0.18	-0.21	-0.22	0.06	-0.15	-0.23	0.05	0.1	0.37	0.04	-0.3	-0.1		-0.24	-0.01	-0.06	0.0	-0.3	-0.17	0.22	-0.29	-0.2	-0.22	0.26	-0.04	0.75
Cash And Short Term Investments	0.98	0.96	0.9	0.5	0.98	0.92	0.13	0.32	0.31	0.66	0.78	0.89	-0.24		0.83	0.65	0.58	0.95	0.85	0.63	0.83	0.93	0.99	-0.09	0.73	-0.33
Net Receivables	0.91	0.85	0.85	0.78	0.86	0.74	0.26	0.57	0.13	0.69	0.49	0.92	-0.01	0.83		0.75	0.68	0.77	0.84	0.67	0.79	0.9	0.87	0.37	0.77	-0.39
Common Stock Shares Outstanding	0.66	0.61	0.62	0.25	0.67	0.63	-0.16	0.87	0.26	0.52	0.04	0.51	-0.06	0.65	0.75		0.99	0.61	0.87	0.91	0.36	0.61	0.72	-0.11	0.24	-0.21
Short Term Investments	0.58	0.54	0.54	0.15	0.6	0.57	-0.2	0.89	0.3	0.47	-0.06	0.42	0.0	0.58	0.68	0.99		0.54	0.82	0.93	0.25	0.52	0.65	-0.17	0.15	-0.12
Non Current Liabilities Total	0.95	0.98	0.91	0.48	0.88	0.87	0.0	0.39	0.15	0.7	0.75	0.87	-0.3	0.95	0.77	0.61	0.54		0.84	0.56	0.81	0.95	0.95	-0.09	0.75	-0.37
Inventory	0.86	0.85	0.78	0.41	0.85	0.83	-0.16	0.67	0.29	0.57	0.42	0.74	-0.17	0.85	0.84	0.87	0.82	0.84		0.74	0.63	0.82	0.9	-0.05	0.52	-0.38
Other Current Assets	0.62	0.56	0.56	0.17	0.66	0.6	-0.06	0.76	0.45	0.54	0.06	0.48	0.22	0.63	0.67	0.91	0.93	0.56	0.74		0.27	0.53	0.67	-0.2	0.22	0.15
Other Stockholder Equity	0.88	0.86	0.83	0.8	0.81	0.72	0.41	0.09	-0.02	0.7	0.83	0.92	-0.29	0.83	0.79	0.36	0.25	0.81	0.63	0.27		0.89	0.83	0.29	0.92	-0.53
Total Liab	0.97	0.98	0.96	0.72	0.88	0.81	0.18	0.41	0.03	0.77	0.73	0.97	-0.2	0.93	0.9	0.61	0.52	0.95	0.82	0.53	0.89		0.94	0.21	0.87	-0.44
Total Current Assets	0.99	0.97	0.91	0.53	0.98	0.92	0.11	0.41	0.3	0.67	0.72	0.9	-0.22	0.99	0.87	0.72	0.65	0.95	0.9	0.67	0.83	0.94		-0.05	0.72	-0.35
Short Term Debt	0.09	0.05	0.15	0.77	-0.04	-0.18	0.39	0.05	-0.43	0.2	0.01	0.33	0.26	-0.09	0.37	-0.11	-0.17	-0.09	-0.05	-0.2	0.29	0.21	-0.05		0.47	-0.27
Intangible Assets	0.81	0.83	0.78	0.86	0.71	0.6	0.41	0.12	-0.02	0.72	0.78	0.92	-0.04	0.73	0.77	0.24	0.15	0.75	0.52	0.22	0.92	0.87	0.72	0.47		-0.39
Common Stock	-0.37	-0.38	-0.42	-0.44	-0.28	-0.25	-0.12	-0.12	0.45	-0.27	-0.32	-0.38	0.75	-0.33	-0.39	-0.21	-0.12	-0.37	-0.38	0.15	-0.53	-0.44	-0.35	-0.27	-0.39

Click cells to compare fundamentals

Pharming Group Account Relationship Matchups

Pharming Group fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	255.6M	419.1M	396.9M	425.8M	462.9M	486.0M
Short Long Term Debt Total	58.1M	162.2M	161.6M	166.7M	171.5M	180.1M
Other Current Liab	20.3M	58.8M	32.0M	42.3M	51.8M	54.4M
Total Current Liabilities	114.1M	77.0M	46.7M	59.7M	78.0M	46.5M
Total Stockholder Equity	117.3M	183.7M	192.7M	204.6M	218.8M	229.7M
Property Plant And Equipment Net	16.3M	21.7M	33.1M	39.1M	33.5M	35.1M
Current Deferred Revenue	34.6M	34.3M	(44.4K)	(56.2K)	(64.7K)	(61.4K)
Net Debt	(16.1M)	(43.3M)	(30.1M)	(40.6M)	109.8M	115.3M
Retained Earnings	(333.4M)	(317.5M)	(269.4M)	(256.4M)	(265.3M)	(278.5M)
Accounts Payable	6.0M	13.5M	5.1M	6.1M	14.5M	7.9M
Cash	74.3M	205.5M	191.7M	207.3M	61.7M	71.7M
Non Current Assets Total	136.3M	155.5M	147.7M	148.3M	146.5M	153.8M
Non Currrent Assets Other	2.5M	510.4K	(303.4K)	1.3M	1.6M	863.7K
Cash And Short Term Investments	74.3M	205.5M	191.7M	207.3M	213.4M	224.1M
Net Receivables	26.3M	19.2M	15.9M	19.6M	32.1M	33.7M
Common Stock Shares Outstanding	67.4M	68.3M	70.1M	70.7M	657.0M	689.9M
Liabilities And Stockholders Equity	255.6M	419.1M	396.9M	425.8M	462.9M	486.0M
Non Current Liabilities Total	24.2M	158.4M	157.5M	161.5M	166.1M	174.4M
Inventory	16.2M	21.2M	27.3M	42.3M	56.8M	59.6M
Other Current Assets	2.6M	5.0M	2.6M	2.5M	13.8M	14.4M
Other Stockholder Equity	439.4M	500.9M	462.7M	462.3M	479.2M	355.2M
Total Liab	138.4M	235.4M	204.2M	221.2M	244.1M	256.3M
Total Current Assets	119.3M	263.6M	249.2M	277.5M	316.3M	332.2M
Short Term Debt	53.2M	4.0M	2.4M	5.2M	5.4M	5.2M
Intangible Assets	79.3M	94.2M	83.8M	75.1M	71.3M	43.1M
Common Stock	7.1M	7.9M	7.3M	7.5M	6.9M	6.6M
Accumulated Other Comprehensive Income	4.2M	5.3M	2.2M	(8.7M)	(2.1M)	(2.0M)
Other Liab	32.7M	17.3M	173K	146K	131.4K	124.8K
Net Tangible Assets	38.2M	77.2M	96.2M	129.5M	148.9M	156.4M
Long Term Debt	0.0	121.9M	122.6M	131.6M	136.6M	95.7M
Capital Lease Obligations	6.3M	8.3M	18.4M	33.3M	33.1M	34.8M
Deferred Long Term Liab	2.2M	4.3M	4.4M	266K	239.4K	227.4K
Net Invested Capital	150.3M	273.0M	294.5M	338.0M	357.2M	258.8M
Short Long Term Debt	45.6M	1.7M	1.7M	1.8M	1.8M	1.7M
Non Current Liabilities Other	32.0M	17.3M	173K	146K	131.4K	124.8K
Net Working Capital	4.6M	151.8M	178.8M	217.8M	238.4M	134.2M
Property Plant Equipment	14.5M	17.6M	29.3M	39.1M	45.0M	47.3M

Additional Tools for Pharming Stock Analysis

When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Pharming Roic vs Roe Analysis

Roic vs Roe

Roic vs Roe Correlation Analysis

Correlation Coefficient

Roic

Roe

Pharming Group fundamental ratios Correlations

Pharming Group Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Pharming Group fundamental ratios Accounts

Additional Tools for Pharming Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Cash And Short Term Investments
Short Term Investments	+ 0.99	Common Stock Shares Outstanding
Short Long Term Debt Total	+ 0.98	Total Assets
Cash And Short Term Investments	+ 0.98	Total Assets
Non Current Liabilities Total	+ 0.98	Short Long Term Debt Total

Common Stock	- 0.53	Other Stockholder Equity
Common Stock	- 0.44	Total Liab
Common Stock	- 0.44	Total Current Liabilities
Short Term Debt	- 0.43	Retained Earnings
Common Stock	- 0.42	Other Current Liab
Common Stock	- 0.39	Intangible Assets